Kellman Selected as FSP on Globeimmune Trials
Kellman Pharmaceutical Services is now working with GlobeImmune as a Functional Service Provider (FSP). GlobeImmune Inc is a private company developing therapeutic vaccines called Tarmogens for the treatment of cancer and infectious diseases. As a FSP, KPS is providing more efficient data management and cost containment expertise through more efficient data monitoring and reporting.
“We were brought in to provide a more efficient monitoring alternative and are succeeding,” explains KPS President David Kelly. “We look forward to expanding our relationship and scope of services for the company in the future.”
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
